Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Flavia Salvi,Stefano Luminari,Alessandra Tucci,Stefania Massidda,Anna Marina Liberati,Caterina Stelitano,Manuela Zanni,Alessandro Re,Riccardo Centurioni,Roberto Freilone,Gerardo Musuraca,Luca Nassi,Caterina Patti,Annalisa Arcari,Monica Tani,Alessandro Pulsoni,Vincenzo Pavone,Stefano Volpetti,Annalisa Peli,Andrea Evangelista,Michele Spina,Marco Ladetto,Francesco Merli

Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

2019

AbstractThis phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of eld...

Keywords:

Doxorubicin
Oncology
Phases of clinical research
Immunology
ABVD Regimen
Toxicity
Liposomal Doxorubicin
Lymphoma
Internal medicine
Medicine
Cardiotoxicity
Dacarbazine
hodgkin lymphoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations